India Glycols Limited has informed the Exchange regarding Outcome of Board Meeting held on May 16, 2025.
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.7 pts less than its Breweries & Distilleries peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
India Glycols Limited reported its audited financial results for Q4 and FY ended March 31, 2025. Standalone revenue from operations grew to Rs. 9,037.82 Cr from Rs. 7,918.77 Cr (~14% YoY), with EBITDA rising to Rs. 521.34 Cr from Rs. 423.48 Cr. Standalone profit after tax stood at Rs. 180.38 Cr (vs Rs. 151.73 Cr), while consolidated PAT jumped to Rs. 230.92 Cr (vs Rs. 172.99 Cr), a ~33% YoY growth driven by a strong Bio-Fuel segment and share of profit from the Clariant IGL joint venture. The Board recommended a dividend of Rs. 10 per share (100% on face value of Rs. 10), subject to shareholder approval. The Board also decided to drop the earlier proposed amalgamation of Kashipur Holdings Limited and will now pursue only the Demerger (separating Bio Pharma and Spirits & Biofuel businesses into Ennature Bio Pharma Ltd and IGL Spirits Ltd), with an appointed date of April 1, 2026.
Positive for shareholders: healthy revenue and profit growth, higher EBITDA margin (~5.8% vs ~5.4% YoY), attractive 100% dividend, and a simpler restructuring path via the standalone Demerger which could unlock value for distinct business verticals.